The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions
Eytan Stein, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, makes the case for bringing the IDH inhibitors ivosidenib and enasidenib to the frontline for acute myeloid leukemia (AML). Dr Stein discusses the results of a Phase I study (NCT02632708) combining either ivosidenib or enasidenib with induction and then consolidation chemotherapy. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Stein emphasizes the efficacy of this treatment, with MRD-negative remissions observed, and outlines the next steps involving a placebo-controlled, randomized Phase III study.
